Tirzepatide, approved by the FDA as Mounjaro for type 2 diabetes and Zepbound for chronic weight management, primarily causes gastrointestinal side effects
ODT formulations specifically have not been studied in clinical trials
Clinical development is underway in the US, for mood disorders in children and adolescents for binge eating disorder and ADHD
In the 1990s, exendin-4, a GLP-1 receptor agonist (GLP-1 RA) structurally similar to endogenous GLP-1, was isolated from Gila monster venom, which subsequently led to the approval of exenatide for type 2 diabetes mellitus (T2DM) management in 2005 [2]
When changing any transdermal patch, patients should remove the old patch carefully, fold it in half with the adhesive sides together, and dispose of it safely according to the medication guidetypically in a sealed container out of reach of children and pets